89bio Shares Upcoming Participation in Notable Conferences
89bio, Inc. (Nasdaq: ETNB), based in San Francisco, is a clinical-stage biopharmaceutical company dedicated to developing unique therapies aimed at treating liver and cardiometabolic diseases. The company has recently announced exciting opportunities for its management to engage with investors through several upcoming conferences.
Details of the Investor Conferences
During September, 89bio will showcase its advancements at multiple investor events, allowing stakeholders to engage with the company’s management team. These conferences will provide insights into the promising innovations within the biopharmaceutical landscape.
Citi’s Biopharma Back to School Conference
One of the significant events is Citi’s 2025 Biopharma Back to School Conference set for September 3. This fireside chat will take place at 11:15 AM EDT, offering a platform for 89bio to present its latest developments directly to investors.
Cantor Global Healthcare Conference
Following this, the Cantor Global Healthcare Conference on September 4 will continue the momentum. Also conducted as a fireside chat, it begins at 11:30 AM EDT, providing further avenues for discussion regarding the company's ongoing work and strategic direction.
H.C. Wainwright 27th Annual Global Investment Conference
The highlight is anticipated on September 8 at the H.C. Wainwright 27th Annual Global Investment Conference, where management will participate in one-on-one meetings. These engagements serve to deepen relationships with current and potential investors, showcasing 89bio's commitment to transparency and open communication.
Accessibility of Conference Webcasts
Investors looking to stay informed can access webcasts of the fireside chats available in 89bio's investor section. Notably, these webcasts will remain available for approximately 30 days following each event, ensuring ample opportunity for stakeholders to gather information at their convenience.
About 89bio and Their Commitment to Healthcare Innovation
89bio is committed to finding the best-in-class therapies for patients suffering from liver and cardiometabolic diseases who currently face limited treatment options. The company is advancing in Phase 3 trials with its lead candidate, pegozafermin, targeting metabolic dysfunction-associated steatohepatitis (MASH) with advanced fibrosis and severe hypertriglyceridemia (SHTG). This drug highlights 89bio's innovative approach, leveraging a specialized fibroblast growth factor 21 (FGF21) analog with a unique glycoPEGylated technology that promises to enhance biological activity through an extended half-life.
Contact Information
For those interested in learning more about 89bio’s work or the upcoming conferences, the company encourages reaching out through the following contacts:
Investor Contacts:
Annie Chang
89bio, Inc.
investors@89bio.com
Eva Bilange
89bio, Inc.
eva.bilange@89bio.com
Media Contact:
Sheryl Seapy
Real Chemistry
sseapy@realchemistry.com
Frequently Asked Questions
What are the upcoming conferences that 89bio is participating in?
89bio is participating in Citi’s 2025 Biopharma Back to School Conference, Cantor Global Healthcare Conference, and H.C. Wainwright 27th Annual Global Investment Conference.
How can investors access the conference webcasts?
The conference webcasts will be available in the investor section of 89bio's website for about 30 days after each event.
What is 89bio’s main therapeutic focus?
89bio focuses on developing therapies for liver and cardiometabolic diseases, particularly through its lead candidate pegozafermin.
Where is 89bio headquartered?
89bio is headquartered in San Francisco.
Who can I contact for more information about 89bio?
Investors can contact Annie Chang or Eva Bilange via their respective email addresses provided in the article.
